Name: GLP-3 -Constituted Peptide Solution
Brand: Aeternum
Price: 111.0 USD
Availability: InStock

GLP-3 vs GLP-2 vs GLP-1

Retatrutide is a triple receptor agonist that targets GLP-1, GIP, and glucagon receptors simultaneously, offering a comprehensive approach to metabolic health.

This unique mechanism of action sets it apart from dual and single receptor agonists, providing enhanced benefits for weight management and metabolic function.

The table below illustrates the key differences in receptor activity across these three therapeutic approaches.

Receptor Activity

Triple

Dual

Single

GLP-1 Receptor Activity

✓

GIP Receptor Activity

✓

✕

Glucagon Receptor Activity

✓

✕

GLP-3 vs GLP-2 vs GLP-1

Retatrutide is a triple receptor agonist that targets GLP-1, GIP, and glucagon receptors simultaneously, offering a comprehensive approach to metabolic health.This unique mechanism of action sets it apart from dual and single receptor agonists, providing enhanced benefits for weight management and metabolic function.The table below illustrates the key differences in receptor activity across these three therapeutic approaches.

Receptor Activity

GLP-1 Receptor Activity

GIP Receptor Activity

Glucagon Receptor Activity

Triple

✓

Dual

✓

✕

Single

✓

✕

DISCOVER MORE

Designed in California, Sourced in Great Britain.

A transatlantic standard in peptide research.

Each batch of GLP-3 is developed across two of the world's most rigorous research environments, combining US scientific design with British precision.

Designed in California
Sourced in Great Britain
Third-Party Purity Verification
Batch-Level Traceability

Format

40mg research peptide

Classification

Triple agonist: GLP-1, GIP & glucagon

Purity

Third-party laboratory tested

Sourcing

Designed in California. Sourced in Great Britain.

Documentation

Certificate of Analysis available upon request

Before You Proceed

GLP-3 is an investigational compound currently under scientific research. It is supplied exclusively for research purposes.

Please review the following carefully:

Not approved for human or veterinary use.

Not for human consumption.

Not intended for diagnosis, treatment or prevention of any condition.

No dosage or administration guidance is provided.

Handle only within appropriate research settings by trained professionals.

Scientific references reflect controlled laboratory research only.

IMPORTANT

Aeternum accepts no responsibility for any use of this compound outside its intended research application.

GLP-3 in Research

GLP-3 is one of the most closely watched compounds in modern science¹ ². As of 2026, it sits at the centre of one of the largest research programs ever assembled around a single molecule⁵ ⁶ with late-stage scientific investigation underway across multiple metabolic², cardiovascular, hepatic, and inflammatory pathways. What's driving the attention is the design itself: a single molecule engaging three metabolic receptors at once¹. Research focuses on how this multi-pathway activation influences interconnected signalling systems that earlier compounds engage only in part⁷.

What Is GLP-3?

GLP-3 is a synthetic peptide designed to engage three metabolic receptors, GLP-1, GIP, and glucagon, within a single molecule. Where earlier peptides target one or two of these pathways, GLP-3 is built to activate all three. That design is the defining feature of current research interest.
Incretin signaling¹ ²
GLP-1 receptor activation is central to the incretin axis, contributing to glucose-dependent insulin secretion and the downstream signalling involved in metabolic regulation.

Nutrient sensing¹ ²

GIP receptor activation is studied for its role in post-prandial signalling, the molecular response that follows nutrient intake, and in modulating insulin release.
Energy substrate handling¹ ³ ⁴
Glucagon receptor activation is studied in relation to hepatic substrate metabolism and energy expenditure pathways. This is the receptor that distinguishes GLP-3 from earlier dual- and single-agonist compounds.

Curated Bio-Optimization Research

Aeternum curates research compounds for the study of cellular signaling, regenerative pathways, and the molecular systems at the foundation of longevity-led research.

Batch Traceability

Quality Over Scale

Dedicated Research Support

ABOUT US

Bio-Optimization Is the Pursuit

GHK-Cu reflects the research. Aeternum sets the standard.

Add to Cart

Select a product in the block settings

Frequently Asked Questions

What is GLP-3?

GLP-3 is an investigational peptide and one of the most studied compounds in modern metabolic research. It is classified as a triple agonist, a single molecule designed to engage three metabolic receptors at once: GLP-1, GIP, and glucagon. Together, these receptors form three of the central signalling axes in metabolic regulation.

Is GLP-3 approved for human use?

No. GHK-Cu is not approved by the MHRA (UK), FDA (US), or any other regulatory authority for human or veterinary use as a therapeutic compound. Aeternum supplies GHK-Cu research material exclusively for research purposes. Not for human consumption.

Why is GLP-3 considered first-in-class?

Most metabolic peptides act on one or two receptors. GLP-3 is the first compound designed to engage three. The addition of glucagon receptor activity, distinct from the two incretin pathways, is the defining feature, bringing a third axis of metabolic signalling into the same molecule.

What makes GLP-3 different from other metabolic peptides?

Reach. Earlier metabolic peptides engage one or two hormone pathways. GLP-3 engages three GLP-1, GIP, and glucagon within a single molecule. The glucagon receptor is the differentiator, bringing energy substrate signalling into a mechanism that already covers the two incretin pathways. No. GLP-3 supplied by Aeternum is intended strictly for research purposes only. We do not provide dosage recommendations, administration guidance, or medical advice. GLP-3 is designed in California and sourced in Great Britain. Each batch is produced across two of the world's most rigorous research environments and undergoes independent third-party purity testing.

Does Aeternum provide dosage guidance?

No. GLP-3 supplied by Aeternum is intended strictly for research purposes only. We do not provide dosage recommendations, administration guidance, or medical advice.

Where is GLP-3 sourced?

GLP-3 is designed in California and sourced in Great Britain. Each batch is produced across two of the world's most rigorous research environments and undergoes independent third-party purity testing.

ASK A QUESTION

More From Aeternum

References

1

Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514–526.
View Source
2

Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet. 2023;402(10401):529–544.
View Source
3

Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30(7):2037–2048.
View Source
4

Coskun T, Wu Q, Schloot NC, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The Lancet Diabetes & Endocrinology. 2025;13(8):674–684.
View Source
5

Giblin K, Kaplan LM, Somers VK, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea, and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes, Obesity and Metabolism. 2025; published online October 15.
View Source
6

A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee (TRIUMPH-4). ClinicalTrials.gov Identifier: NCT05931367.
View Source
7

Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021;385(6):503–515.
View Source

Precision peptides. Elite standards. Designed for a higher standard of living.

Explore

SHOP

Links

STAY INFORMED

Exclusive insights on science, products, and protocols.

Website Developed by demo

GLP-3 -Constituted Peptide Solution

Safe & Secure Checkout

GLP-3 vs GLP-2 vs GLP-1

GLP-3 vs GLP-2 vs GLP-1

Designed in California, Sourced in Great Britain.

Format

Classification

Purity

Sourcing

Documentation

Before You Proceed

GLP-3 in Research

What Is GLP-3?

Nutrient sensing¹ ²

Curated Bio-Optimization Research

Bio-Optimization Is the Pursuit

Frequently Asked Questions

References

Explore

SHOP

Links

STAY INFORMED